The development of novel pharmaceuticals, particularly in areas like cardiovascular disease, relies heavily on the availability of highly specific and pure chemical intermediates. One such critical compound is (5R,9S)-9-Amino-21-(Difluoromethyl)-5-Methyl-21H-3-Aza-1(4,2)-Pyridina-2(5,4)-Pyrazolacyclononaphan-4-One, identified by CAS Number 1802431-24-8. This intermediate plays a pivotal role in the synthesis of Milvexian, a promising therapeutic agent targeting cardiovascular conditions.

The Role of CAS 1802431-24-8 in Milvexian Synthesis

Milvexian is a factor XIa inhibitor, an anticoagulant designed to offer a new approach to preventing thrombotic events. The synthesis of such complex molecules requires highly specialized building blocks, and the intermediate with CAS 1802431-24-8 is precisely that. Its unique structure, featuring chiral centers and specific functional groups, makes it indispensable for constructing the Milvexian molecule. For pharmaceutical companies engaged in the research and development of cardiovascular drugs, securing a consistent and high-quality supply of this intermediate is crucial. Pharmaceutical intermediate manufacturers in China are key players in providing these essential chemical precursors. Researchers often search for terms like “buy Milvexian intermediate China” or “pharmaceutical intermediate manufacturer CAS 1802431-24-8” to identify reliable sources.

Quality and Sourcing Considerations for Researchers and Buyers

When sourcing this critical intermediate, buyers must prioritize purity and manufacturing standards. A purity level exceeding 98%, coupled with certifications like GMP, ISO 9001, and FDA approval, ensures that the intermediate meets the stringent requirements of pharmaceutical manufacturing. These certifications are testaments to the supplier's adherence to quality control and regulatory compliance. Companies looking to purchase this intermediate often seek “high purity Milvexian intermediate for sale” or inquire about custom synthesis services if specific modifications are needed for their research. Engaging with suppliers who provide detailed technical documentation and support is also vital.

The Importance of a Stable Supply Chain

The journey from laboratory synthesis to commercial production of a new drug involves many stages, and a stable supply chain for intermediates is fundamental. A reliable manufacturer with substantial production capacity (e.g., 1000kg/year) can ensure that research and production timelines are met without interruption. For procurement managers, identifying “Milvexian intermediate suppliers” who can guarantee timely delivery and consistent quality is a top priority. Establishing partnerships with manufacturers who offer flexible solutions, including custom synthesis and reliable logistics, is key to successful drug development.

Conclusion

The pharmaceutical intermediate (5R,9S)-9-Amino-21-(Difluoromethyl)-5-Methyl-21H-3-Aza-1(4,2)-Pyridina-2(5,4)-Pyrazolacyclononaphan-4-One (CAS 1802431-24-8) is a cornerstone in the development of advanced cardiovascular therapies like Milvexian. By understanding the importance of purity, certifications, and reliable sourcing from qualified manufacturers, researchers and procurement specialists can effectively acquire the materials needed to advance critical drug development projects.